- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01290315
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a Phase 2a, open-label, multicenter, randomized study that compared the safety and oxidative stress potential of FCM vs. IV iron sucrose or IV iron dextran in female subjects with IDA. Subjects with a diagnosis of IDA who required iron supplementation met all inclusion and no exclusion criteria, and had given informed consent were randomized. The duration of the study for each subject was a maximum of 6 weeks.
Eligible subjects were randomized in a 1:1 ratio to FCM (Group A) or IV iron sucrose or IV iron dextran (Group B).
Group A subjects received a single undiluted dose of iron as FCM by a slow IV injection on Day 0. Cohort I received 500 mg and Cohort II received 750 mg. Group B subjects received a single dose of iron as IV iron sucrose or as IC iron dextran on Day 0. Cohort I receive 500 mg iron sucrose and Cohort II received 750 mg iron dextran. Iron dextran administration was preceded by a 25 mg test dose 1 hour prior to infusion.
All subjects had laboratory assessments at Baseline, 2 hours post-infusion, 24 hours post-infusion, Day 7 (drawn at the same time of day [within 4 hours] as the 24-hour visit), and Day 30 (drawn at the same time of day [within 4 hours] as the the 24-hour visit). On Days 7 and 30, the safety evalutation for all subjects included treatment-emergent adverse event reporting, concomitant medication review, physical examination including vital signs, and laboratory assessments. Any subject who withdrew from the study received a follow-up phone call 30 days after they received study drug.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Norristown, Pennsylvania, United States, 19403
- Luitpold Pharmaceuticals, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects 18-50 years of age and able to give informed consent.
- If post-partum, at least 10 days post delivery at Day 0.
- Screening Visit local laboratory Hgb < or = to 10 g/dL or < or = to 12 g/dL with symptoms (dizziness and/or fatigue).
- Screening Visit ferritin < or = to 100 ng/mL or < or = to 300 when TSAT is < or = to 30%.
- Documented unsatisfactory response or intolerance to oral iron.
Exclusion Criteria:
- Previous participation in a ferric carboxymaltose (FCM) clinical trial.
- Known hypersensitivity reaction to any component of ferric carboxymaltose, Venofer, or Dexferrum.
- History of drug allergy or any history of rheumatoid arthritis or other autoimmune diseases.
- Current anemia not attributed to iron deficiency.
- During the 10 day period prior to screening has been treated with antibiotics.
- During the 30 day period prior to screening or during the study period has or will be treated with erythropoiesis stimulating agents.
- Active malignancy within 5 years. Basal or squamous cell skin cancer is not exclusionary.
- During the 30 day period prior to screening or during the study period has or will require a surgical procedure that necessitates general anesthesia.
- Current (acute or chronic) infection other than viral upper respiratory tract infection.
- AST or ALT at screening greater than 1.5 times the upper limit of normal.
- Known positive hepatitis B with evidence of active hepatitis.
- Known positive HIV-1/HIV-2 antibodies (anti-HIV).
- Patient has an active diagnosis of asthma and is currently using an anti- asthmatic therapy.
- Received an investigational drug within 30 days of screening.
- Alcohol or drug abuse within the past 6 months.
- Hemochromatosis or other iron storage disorders.
- Systolic blood pressure > or = to 180 or < 80 mmHg or diastolic blood pressure > or = to 100 or < 40 mmHg at screening or Day 0.
- Chronic kidney disease.
- Chronic inflammatory condition including but not limited to Lupus and Rheumatoid Arthritis.
- Pre-term delivery < 32 weeks.
- Emergent C-section delivery.
- Significant cardiovascular disease, including but not limited to myocardial infarction or unstable angina within 6 months prior to study inclusion or current history of NYHA Class III or IV congestive heart failure.
- Any other laboratory abnormality, medical condition or psychiatric disorder which in the opinion of the investigator puts the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
- Night shift workers.
- Breastfeeding planned on or after Day 0.
- Pregnant or sexually-active female subjects who are of childbearing potential and who don't use an acceptable form of contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ferric Carboxymaltose (FCM)
Intravenous iron
|
One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
Other Names:
|
Active Comparator: Iron Sucrose / Iron Dextran
Intravenous iron
|
One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time Frame: Change from Baseline to Day 30
|
Change from Baseline to Day 30
|
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time Frame: Change from baseline to 2 hours post end IV infusion
|
Change from baseline to 2 hours post end IV infusion
|
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time Frame: Change from baseline to 24 hours post end IV infusion
|
Change from baseline to 24 hours post end IV infusion
|
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time Frame: Change from baseline to Day 7 post end IV infusion
|
Change from baseline to Day 7 post end IV infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Linda M Mundy, MD, PhD, American Regent, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1VIT08022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency Anemia
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Luzerner KantonsspitalRecruitingIron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron DeficienciesSwitzerland
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
-
Swiss Federal Institute of TechnologyUniversity of MalawiCompletedIron-deficiency | Iron Deficiency AnemiaMalawi, Switzerland
Clinical Trials on Ferric Carboxymaltose (FCM)
-
American Regent, Inc.Completed
-
American Regent, Inc.CompletedIron Deficiency Anemia (IDA)Poland, Russian Federation
-
King Hussein Cancer CenterHikma Pharmaceuticals LLCCompleted
-
American Regent, Inc.National Institute on Aging (NIA)Completed
-
Vifor PharmaICON Clinical Research; American Regent, Inc.CompletedChronic Kidney Disease | Iron Deficiency AnaemiaUnited Kingdom, United States, Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
-
American Regent, Inc.CompletedIron Deficiency Anemia | Impaired Renal FunctionUnited States
-
American Regent, Inc.Completed
-
American Regent, Inc.CompletedPostpartum AnemiaUnited States
-
American Regent, Inc.CompletedFibromyalgia | Iron DeficiencyUnited States